Immunome, Inc.
IMNM
$8.49
$0.030.36%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 11.60% | -174.29% | -1,290.60% | -904.33% | -686.19% |
| Total Depreciation and Amortization | 204.27% | 188.74% | 141.31% | 100.15% | 31.10% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -71.59% | 90.95% | 4,191.39% | 4,080.49% | 3,690.77% |
| Change in Net Operating Assets | 37.34% | 23.98% | -91.43% | -125.94% | -141.56% |
| Cash from Operations | -255.80% | -1,363.98% | -2,786.81% | -1,526.49% | -2,408.28% |
| Capital Expenditure | -1,804.08% | -6,338.99% | -9,373.29% | -844.59% | -730.17% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 278.04% | 278.04% | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 69.19% | -71.14% | -- | -- | -- |
| Cash from Investing | 36.78% | -179.04% | -22,431.23% | -28,656.18% | -19,327.87% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -16.71% | 63,049.88% | 692,967.65% | 691,470.59% | 688,050.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -111.35% | -113.13% | -33.80% | -- | -- |
| Cash from Financing | -45.41% | 106.63% | 353.04% | 989,644.12% | 987,602.94% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -105.38% | -42.99% | 2.15% | 3,269.15% | 14,482.46% |